AVI BioPharma's Antisense Drugs Found Effective Against Lethal Virus
Posted on: Wednesday, 14 May 2008, 12:00 CDT
AVI BioPharma has announced that treatment of non-human primates with either the antisense drug AVI-6002 or with the antisense drug AVI-6003, resulted in a reproducible and high rate of survival in the face of an otherwise lethal infection with Ebola or Marburg virus, respectively.
In repeated trials, monkeys were dosed with well-tolerated amounts of drug and survived a challenge of roughly 1000 times the minimum lethal dose. This level of infectious challenge normally results in uniform death of unprotected monkeys within 7 to 10 days. Treatment of Ebola infected animals with AVI-6002 resulted in 75% survival of the infected animals at 15 days post infection when the treatment period ended and circulating viral titer was below detectable levels. Treatment of Marburg infected animals with AVI-6003 resulted in 100% survival at 15 days.
The studies utilized experimental drugs based on a novel variation of AVI's proprietary NeuGene chemistry referred to as NeuGene Plus in which anti-viral potency was enhanced by the addition of positively-charged components to the morpholino backbone. These new data are a result of continued studies conducted in collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
George Korch, Jr., commander of USAMRIID, said: "Since the discovery of these viruses in 1967, no prior therapeutic approach has resulted in this level of survival in non-human primates. We look forward to working with AVI to advance these drug candidates with the ultimate goal of submitting them for FDA approval."
Source: Datamonitor
Related Articles
- PNY and National Geographic Celebrate World Animal Day at Local Zoos
- InforMedix and Rodman's Discount Drug Store Partner For a Demo Day to Promote Safe Medication Use in Seniors Featuring the Med-eMonitor ``Smart Pillbox''
- AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals
- Many Diagnostics (E.G., Phenotypic Tests, Molecular Tests) Are Now Available to Detect Pathogens and Determine Antibiotic Susceptibility - Identifying Drug-Resistant Bacterial Infections
- Tissera Reports Further Encouraging Results of Its Ongoing Large Animal Experiments of Pancreatic Xenotransplantation
- Paying for HIV Drugs Endangers Treatment: MSF
- Tissera Reports Encouraging Interim Results of Its Ongoing Large Animal Experiments of Pancreatic Xenotransplantation
- Non-Drug Hypertension Treatment Device Effectively Reduces Blood Pressure in Hypertensive Diabetics; Interim Results From a Randomized Controlled Study Suggest a New Treatment Option
- The Cognitive Effects of Cholinesterase Inhibitor Treatment in Every- Day Practice
- White-Coat Effect is Virtually Eliminated Using a Non-Drug Hypertension Treatment Device
 |
 |
User Comments (0)
RSS Feeds